ALDX (Aldeyra Therapeutics) Shiller PE Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALDX Aldeyra Therapeutics Inc ALDX
30 GF Score
Price $1.52
! 1 Warning Sign
View Full Analysis

What is Aldeyra Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aldeyra Therapeutics  (NAS:ALDX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aldeyra Therapeutics Shiller PE Ratio Related Terms


Aldeyra Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics Shiller PE Ratio Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aldeyra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ALDX vs NTHI, BMEA, PTHS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Shiller PE Ratio falls into.


ALDX
30GF Score
Aldeyra Therapeutics Inc ALDX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aldeyra Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Aldeyra Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.09/333.9520*333.9520
=-0.090

Current CPI (Jun. 2026) = 333.9520.

Aldeyra Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.380 241.428 -0.526
201612 -0.370 241.432 -0.512
201703 -0.370 243.801 -0.507
201706 -0.350 244.955 -0.477
201709 -0.320 246.819 -0.433
201712 -0.360 246.524 -0.488
201803 -0.430 249.554 -0.575
201806 -0.460 251.989 -0.610
201809 -0.520 252.439 -0.688
201812 -0.390 251.233 -0.518
201903 -0.580 254.202 -0.762
201906 -0.490 256.143 -0.639
201909 -0.690 256.759 -0.897
201912 -0.470 256.974 -0.611
202003 -0.340 258.115 -0.440
202006 -0.250 257.797 -0.324
202009 -0.230 260.280 -0.295
202012 -0.300 260.474 -0.385
202103 -0.250 264.877 -0.315
202106 -0.280 271.696 -0.344
202109 -0.270 274.310 -0.329
202112 -0.270 278.802 -0.323
202203 -0.290 287.504 -0.337
202206 -0.300 296.311 -0.338
202209 -0.250 296.808 -0.281
202212 -0.220 296.797 -0.248
202303 -0.270 301.836 -0.299
202306 -0.150 305.109 -0.164
202309 -0.140 307.789 -0.152
202312 -0.080 306.746 -0.087
202403 -0.140 312.332 -0.150
202406 -0.280 314.175 -0.298
202409 -0.250 315.301 -0.265
202412 -0.270 315.605 -0.286
202503 -0.170 319.799 -0.178
202506 -0.160 322.561 -0.166
202509 -0.130 324.800 -0.134
202512 -0.100 324.054 -0.103
202603 -0.060 330.213 -0.061
202606 -0.090 333.952 -0.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aldeyra Therapeutics Business Description

Other Exchanges 137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
30GF Score

Get the complete analysis for ALDX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price